Search results for "LIPID"

showing 10 items of 3879 documents

Sterols in human milk during lactation: bioaccessibility and estimated intakes.

2018

Human milk (HM) is the exclusive food during the first 4–6 months of an infant's life. Breastfeeding has been related to significant health benefits for infants, and hence it is of interest to study the bioactive compounds present in HM, such as sterols (cholesterol being the most abundant). The aim of this study was to determine the contents of sterols (cholesterol, desmosterol, lathosterol, lanosterol, campesterol, stigmasterol and β-sitosterol) in 10 pools of colostrum, transitional milk, and 1, 3 and 6 month HM obtained from Spanish volunteers from two different geographical areas (coastal and central) and to estimate the intake and bioaccessibility (BA) of sterols in order to ascertain…

0301 basic medicineAdultAdolescentCampesterolLathosterolBiology03 medical and health scienceschemistry.chemical_compoundYoung AdultAnimal sciencePregnancyLactationDesmosterolpolycyclic compoundsmedicineHumansLactation030109 nutrition & dieteticsStigmasterolMilk HumanCholesterolColostrumInfantGeneral MedicineSterolSterolsmedicine.anatomical_structureBreast FeedingCholesterolchemistryColostrumlipids (amino acids peptides and proteins)FemaleFood ScienceFoodfunction
researchProduct

Autosomal recessive hypercholesterolemia in Spain.

2017

Abstract Background and aims Autosomal recessive hypercholesterolemia (ARH) is a very rare disease, caused by mutations in LDL protein receptor adaptor 1 (LDLRAP1). It is characterized by high levels of low-density lipoprotein cholesterol (LDL-C) and increased risk of premature cardiovascular disease. We aimed to characterize ARH in Spain. Methods Data were collected from the Dyslipidemia Registry of the Spanish Atherosclerosis Society. A literature search was performed up to June 2017, and all diagnostic genetic studies for familial hypercholesterolemia of Spain were reviewed. Results Seven patients with ARH were identified, 6 true homozygous and one compound heterozygous with a novel muta…

0301 basic medicineAdultGenetic MarkersMalemedicine.medical_specialtyHeterozygoteHypercholesterolemiaDiseaseFamilial hypercholesterolemia030204 cardiovascular system & hematologyCompound heterozygosity03 medical and health sciences0302 clinical medicineInternal medicinemedicinePrevalenceHumansGenetic Predisposition to DiseaseRegistriesChildAdaptor Proteins Signal TransducingHypolipidemic Agentsbusiness.industryGenetic heterogeneityHomozygoteInfantCholesterol LDLMiddle Agedmedicine.diseaseAtherosclerosisUp-Regulation030104 developmental biologyEndocrinologyPhenotypeAutosomal Recessive HypercholesterolemiaSpainChild PreschoolCohortMutationDisease ProgressionFemaleCardiology and Cardiovascular MedicinebusinessDyslipidemiaRare diseaseAtherosclerosis
researchProduct

Systemic redox biomarkers and their relationship to prognostic risk markers in autosomal dominant polycystic kidney disease and IgA nephropathy.

2017

Abstract Background Oxidative stress is evident from an early stage in chronic kidney disease (CKD). Therefore, we investigated redox biomarkers in polycystic kidney disease (ADPKD) and IgA nephropathy (IGAN). Methods This is a case-control study with three groups: ADPKD (n = 54), IGAN (n = 58) and healthy controls (n = 86). The major plasma aminothiols with their redox species were examined: homocysteine (Hcy), cysteinglycine (CG), cysteine (Cys) and glutathione (GSH). The redox ratio was the ratio of reduced free and oxidized aminothiols in plasma. We investigated malonedialdehyde (MDA) and advanced oxidation protein products (AOPP), and ten single nucleotide polymorphisms of antioxidant …

0301 basic medicineAdultMaleRiskmedicine.medical_specialtyHomocysteineClinical Biochemistry030232 urology & nephrologyAutosomal dominant polycystic kidney diseaseurologic and male genital diseasesmedicine.disease_causePolymorphism Single NucleotideNephropathy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinePolycystic kidney diseaseMedicineHumansHomocysteineGenetic Association StudiesProteinuriabusiness.industrySuperoxide DismutaseGlomerulonephritis IGAGeneral MedicineDipeptidesMiddle Agedmedicine.diseasePolycystic Kidney Autosomal DominantPrognosisOxidative Stress030104 developmental biologyEndocrinologychemistryAdvanced Oxidation Protein ProductsCase-Control StudiesDisease ProgressionFemaleGene polymorphismLipid Peroxidationmedicine.symptombusinessOxidoreductasesOxidation-ReductionOxidative stressBiomarkersKidney diseaseClinical biochemistry
researchProduct

Resting Energy Expenditure and Substrate Oxidation in Malnourished Patients With Type 1 Glycogenosis.

2019

Abstract Context Type 1a and 1b glycogenosis [glycogen storage disorder (GSD)1a, GSD1b] are rare diseases generally associated with malnutrition. Although abnormal substrate oxidation rates and elevated energy expenditures might contribute to malnutrition, this issue has not been investigated. Objective To investigate whether abnormal resting energy expenditure (REE) and substrate oxidation rate characterize patients with GSD1. Design Cross-sectional study Setting Outpatient referral center for rare diseases and laboratory of clinical nutrition at the University Hospital of Palermo Patients Five consecutive patients with GSD1 (4 type a, 1 type b; 3 men, 2 women; age range, 19 to 49 years) M…

0301 basic medicineAdultMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismClinical Biochemistry030209 endocrinology & metabolismClinical nutritionmalnoutritionGlycogen Storage Disease Type IProtein oxidationBiochemistryGastroenterology03 medical and health sciencesBasal (phylogenetics)chemistry.chemical_compoundYoung Adult0302 clinical medicineEndocrinologyOxygen ConsumptionLipid oxidationsubstrate oxidationInternal medicineMedicineHumansResting energy expenditureSettore MED/49 - Scienze Tecniche Dietetiche ApplicateResting energy expenditureGlycogenbusiness.industryBiochemistry (medical)MalnutritionCalorimetry IndirectCarbohydratetype 1 glycogenosis.Middle Agedmedicine.diseaseMalnutrition030104 developmental biologyEndocrinologyCross-Sectional StudieschemistryBody CompositionFemalebusinessEnergy MetabolismOxidation-ReductionThe Journal of clinical endocrinology and metabolism
researchProduct

Effects of the flavonol quercetin and α-linolenic acid on n-3 PUFA status in metabolically healthy men and women: a randomised, double-blinded, place…

2017

AbstractIncreased dietary intake and tissue status of the long-chainn-3 PUFA, EPA and DHA, is associated with cardiovascular benefits. Epidemiological and animal studies suggest that concomitant nutritive intake of flavonoids may increase the conversion ofα-linolenic acid (ALA) to longer-chainn-3 fatty acids EPA and DHA. We investigated the effects of increased ALA intake on fatty acid composition of serum phospholipids and erythrocytes in metabolically healthy men and women and whether fatty acid profiles and ALA conversion were affected by regular quercetin intake or sex. Subjects (n74) were randomised to receive at least 3·3 g/d ALA with either 190 mg/d quercetin (ALA+quercetin) or place…

0301 basic medicineAdultMalemedicine.medical_specialtyErythrocytesDocosahexaenoic AcidsMedicine (miscellaneous)PlaceboPlacebos03 medical and health scienceschemistry.chemical_compoundDouble-Blind MethodInternal medicineFatty Acids Omega-3MedicineHumansN 3 pufaPhospholipidsα-linolenic acidchemistry.chemical_classification030109 nutrition & dieteticsNutrition and DieteticsCross-Over Studiesbusiness.industryFatty AcidsFatty acidalpha-Linolenic AcidCrossover studyDietEndocrinologychemistryBiochemistryEicosapentaenoic AcidDietary SupplementsBody Compositionlipids (amino acids peptides and proteins)FemaleQuercetinAnimal studiesbusinessQuercetinPolyunsaturated fatty acidThe British journal of nutrition
researchProduct

Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Fou…

2018

Objectives: The management of HIV disease is complicated by the incidence of a new spectrum of comorbid noncommunicable diseases (NCDs). It is important to document changes in the prevalence of NCDs over time. The aim of the study was to describe the impact of ageing on HIV markers and on the prevalence of NCDs in people living with HIV (PLWHIV) in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) seen for care in 2004–2014. Methods: Analyses were conducted separately for a closed cohort (same people seen at both times) and an open cohort (all people under follow-up). We used the χ2 test for categorical factors and the Wilcoxon test for quantitative factors to compare pro…

0301 basic medicineAdultMalemedicine.medical_specialtynoncommunicable diseases (NCDs); persons living with HIV (PLWHIV); time trend; Health Policy; Infectious Diseases; Pharmacology (medical)persons living with HIV (PLWHIV)PopulationRenal functionInfectious DiseaseHIV InfectionsDiseaseComorbiditySettore MED/17 - MALATTIE INFETTIVENO03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicinePrevalenceMedicineHiv infected patientsHumansPharmacology (medical)030212 general & internal medicineeducationDyslipidemiaseducation.field_of_studynoncommunicable diseases (NCDs); persons living with HIV (PLWHIV); time trendFramingham Risk Scorebusiness.industryIncidence (epidemiology)Health Policynoncommunicable diseases (NCDs) persons living with HIV (PLWHIV) time trendMiddle Aged030112 virologytime trendInfectious DiseasesItalyCardiovascular DiseasesCohortHypertensionFemalebusinessnoncommunicable diseases (NCDs)HIV medicine
researchProduct

Cholesterol Hydroxylating Cytochrome P450 46A1: From Mechanisms of Action to Clinical Applications

2021

Cholesterol, an essential component of the brain, and its local metabolism are involved in many neurodegenerative diseases. The blood-brain barrier is impermeable to cholesterol; hence, cholesterol homeostasis in the central nervous system represents a balance betweenin situbiosynthesis and elimination. Cytochrome P450 46A1 (CYP46A1), a central nervous system-specific enzyme, converts cholesterol to 24-hydroxycholesterol, which can freely cross the blood-brain barrier and be degraded in the liver. By the dual action of initiating cholesterol efflux and activating the cholesterol synthesis pathway, CYP46A1 is the key enzyme that ensures brain cholesterol turnover. In humans and mouse models,…

0301 basic medicineAgingCognitive Neuroscience24-hydroxycholesterolbrain[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/NeurobiologyCentral nervous systemNeurosciences. Biological psychiatry. NeuropsychiatryReview03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineneurodegenerative diseasesAmyotrophic lateral sclerosisLipid raftlipid raftsbiologyCholesterolbusiness.industryphosphorylation[SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/NeurobiologyCytochrome P450cholesterolmedicine.diseaseplasma membranes3. Good healthVesicular transport proteinCYP46A1030104 developmental biologymedicine.anatomical_structurechemistrySpinocerebellar ataxiabiology.proteinAnimal studiesbusinessNeuroscience030217 neurology & neurosurgeryNeuroscienceRC321-571
researchProduct

Interactive effects of aging and aerobic capacity on energy metabolism-related metabolites of serum, skeletal muscle, and white adipose tissue

2021

ABSTRACTAerobic capacity is a strong predictor of longevity. With aging, aerobic capacity decreases concomitantly with changes in whole body metabolism leading to increased disease risk. To address the role of aerobic capacity, aging and their interaction on metabolism, we utilized rat models of low and high intrinsic aerobic capacity (LCRs/HCRs) and assessed the metabolomics of serum, muscle, and white adipose tissue (WAT). We compared LCRs and HCRs at two time points: Young rats were sacrificed at 9 months, and old rats were sacrificed at 21 months. Targeted and semi-quantitative metabolomics analysis was performed on ultra-pressure Liquid Chromatography Tandem Mass Spectrometry (UPLC-MS)…

0301 basic medicineAgingWhite adipose tissue030204 cardiovascular system & hematologychemistry.chemical_compound0302 clinical medicineTandem Mass SpectrometryMetabolitesaineenvaihduntametabolitesALL-CAUSE MORTALITY2. Zero hungerchemistry.chemical_classification0303 health sciencesmetabolomicsAmino acidmedicine.anatomical_structureCARDIOVASCULAR-DISEASEOBESITYaerobinen suorituskykyOriginal ArticleCARDIORESPIRATORY FITNESSARTIFICIAL SELECTIONmedicine.medical_specialtyAdipose Tissue WhiteEXERCISErasva-aineenvaihdunta03 medical and health sciencesMetabolomicsFATNESSAerobic capacityInternal medicinemedicineAnimalsMetabolomicsBeta (finance)Muscle SkeletalAerobic capacity030304 developmental biologyAMINO-ACID-METABOLISMFatty acid metabolismagingSkeletal muscleLipid metabolismCardiorespiratory fitnessMetabolismRatsaerobic capacityikääntyminen030104 developmental biologyEndocrinologyPHYSICAL-ACTIVITYchemistryFUEL SELECTIONaineenvaihduntatuotteet3111 Biomedicinekoe-eläinmallitGeriatrics and GerontologyEnergy MetabolismChromatography Liquid
researchProduct

Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats

2019

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-2 (GLP-2) are hormones secreted from the enteroendocrine cells after a meal. They exert their actions through activation of G protein-coupled receptors (R), the GIPR and GLP-2R, respectively. Both have been reported to influence metabolism. The purpose of the study was to investigate the role of the hormones in the regulation of lipid and bone homeostasis by subchronic treatment with novel GIPR and GLP-2R antagonists. Rats were injected once daily with vehicle, GIPR, or GLP-2R antagonists for 3 weeks. Body weight, food intake, body composition, plasma lipoprotein lipase (LPL), adipokines, triglycerides and the mark…

0301 basic medicineAgonistmedicine.medical_specialtyendocrine systemmedicine.drug_classEndocrinology Diabetes and MetabolismAdipokine030209 endocrinology & metabolismSettore BIO/09 - Fisiologialcsh:Diseases of the endocrine glands. Clinical endocrinologyBone resorption03 medical and health sciencesEndocrinology0302 clinical medicineInternal medicinemedicineglucagon-like peptide-2 (GLP-2)ReceptorOriginal Researchlcsh:RC648-665ChemistryLeptindigestive oral and skin physiologyAntagonistGIP receptorGIP receptor antagonistReceptor antagonistlipid homeostasis030104 developmental biologyEndocrinologyglucose-dependent insulinotropic polypeptide (GIP)hormones hormone substitutes and hormone antagonistsHormoneFrontiers in Endocrinology
researchProduct

The endocannabinoid-alcohol crosstalk: Recent advances on a bi-faceted target

2018

Increasing evidence has focusesed on the endocannabinoid system as a relevant player in the induction of aberrant synaptic plasticity and related addictive phenotype following chronic excessive alcohol drinking. In addition, the endocannabinoid system is implicated in the pathogenesis of alcoholic liver disease. Interestingly, whereas the involvement of CB1 receptors in alcohol rewarding properties is established, the central and peripheral action of CB2 signalling is still to be elucidated. This review aims at giving the input to deepen knowledge on the role of the endocannabinoid system, highlighting the advancing evidence that suggests that CB1 and CB2 receptors may play opposite roles i…

0301 basic medicineAlcoholic liver diseaseCannabinoid receptorSettore BIO/14 - FARMACOLOGIAPhysiologybrain12Inflammationliver03 medical and health sciences0302 clinical medicinePhysiology (medical)Cannabinoid receptor type 2MedicineCB; 2CB; 1endocannabinoidsReceptorPharmacologybusiness.industryalcoholmusculoskeletal neural and ocular physiologyendocannabinoidmedicine.diseaseEndocannabinoid systemCBCrosstalk (biology)030104 developmental biologynervous systemSynaptic plasticitylipids (amino acids peptides and proteins)medicine.symptombusinessNeurosciencepsychological phenomena and processes030217 neurology & neurosurgery
researchProduct